# Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) Prognostic and Natural History Study (PNHS)

First published: 08/04/2024

**Last updated:** 17/10/2024







# Administrative details

# Administrative details

#### **PURI**

https://redirect.ema.europa.eu/resource/1000000027

#### **Data source ID**

100000027

# Data source acronym

**AMYPAD PNHS** 

#### **Data holder**

Amsterdam UMC

# **Data source type**

Other

# Data source type, other

Research Cohort

# Main financial support

European public funding

# **Care setting**

Other

# **Data source qualification**

If the data source has successfully undergone a formal qualification process (e.g., from the EMA, ISO or other certifications), this should be described.

No

#### **Data source website**

https://amypad.eu/project/amypad-pnhs/

# Contact details

# David Vállez García



amypad.pnhs@amsterdamumc.nl

# Frederik Barkhof



f.barkhof@amsterdamumc.nl

# Data source regions and languages

#### **Data source countries**

Belgium

France

Germany

Greece

Italy

Netherlands

Spain

Sweden

Switzerland

United Kingdom

# **Data source languages**

English

# Data source establishment

# Data source time span

First collection: 16/12/1986

The date when data started to be collected or extracted.

# **Publications**

# Data source publications

Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study

Recruitment of pre-dementia participants: main enrollment barriers in a longitudinal amyloid-PET study

The amyloid imaging for the prevention of Alzheimer's disease consortium: A European collaboration with global impact

# Data elements collected

# The data source contains the following information

# **Disease information**

Does the data source collect information with a focus on a specific disease? This might be a patient registry or other similar initiatives.

Yes

# Disease details (other)

Alzheimer's disease

#### **Rare diseases**

Are rare diseases captured? In the European Union a rare disease is one that affects no more than 5 people in 10,000.

No

# Pregnancy and/or neonates

Does the data source collect information on pregnant women and/or neonatal subpopulation (under 28 days of age)?

No

# Hospital admission and/or discharge

No

#### ICU admission

Is information on intensive care unit admission available?

No

#### **Cause of death**

Not Captured

# **Prescriptions of medicines**

Not Captured

# **Dispensing of medicines**

Not Captured

# Advanced therapy medicinal products (ATMP)

Is information on advanced therapy medicinal products included? A medicinal product for human use that is either a gene therapy medicinal product, a somatic cell therapy product or a tissue engineered products as defined in Regulation (EC) No 1394/2007 [Reg (EC) No 1394/2007 Art 1(1)].

No

# **Contraception**

Is information on the use of any type of contraception (oral, injectable, devices etc.) available?

No

#### Indication for use

Does the data source capture information on the therapeutic indication for the use of medicinal products?

Not Captured

#### **Medical devices**

Is information on medicinal devices (e.g., pens, syringes, inhalers) available?

No

#### **Administration of vaccines**

No

#### **Procedures**

Does the data source capture information on procedures (e.g., diagnostic tests, therapeutic, surgical interventions)?

Captured

# **Procedures vocabulary**

Other

# Procedures vocabulary, other

Custom (AMYPAD)

# **Healthcare** provider

Is information on the person providing healthcare (e.g., physician, pharmacist, specialist) available? The healthcare provider refers to individual health professionals or a health facility organisation licensed to provide health care diagnosis and treatment services including medication, surgery and medical devices.

No

#### **Clinical measurements**

Is information on clinical measurements (e.g., BMI, blood pressure, height) available?

Yes

#### **Genetic data**

Are data related to genotyping, genome sequencing available?

Captured

# **Genetic data vocabulary**

Other

# Genetic data vocabulary, other

**OMOP** 

#### **Biomarker data**

Does the data source capture biomarker information? The term "biomarker" refers to a broad subcategory of medical signs (objective indications of medical state observed from outside the patient), which can be measured accurately and reproducibly. For example, haematological assays, infectious disease markers or metabolomic biomarkers.

Captured

# Biomarker data vocabulary

Other

# Biomarker vocabulary, other

LOINC

# **Patient-reported outcomes**

Is information on patient-reported outcomes (e.g., quality of life) available?

Yes

# Patient-generated data

Is patient-generated information (e.g., from wearable devices) available?

No

#### Units of healthcare utilisation

Are units of healthcare utilisation (e.g., number of visits to GP per year, number of hospital days) available or can they be derived? Units of healthcare utilisation refer to the quantification of the use of services for the purpose of preventing or curing health problems.

No

# **Unique identifier for persons**

Are patients uniquely identified in the data	source?
Yes	

# **Diagnostic codes**

Not Captured

# **Medicinal product information**

Not Captured

# **Quality of life measurements**

Not Captured

# **Lifestyle factors**

Captured

# **Lifestyle factors**

Alcohol use

Diet

Frequency of exercise

Other

Tobacco use

# **Sociodemographic information**

Captured

# Sociodemographic information collected

Age

Education level

Ethnicity

Gender

Marital status

# Quantitative descriptors

# **Population age groups**

Adults (46 to < 65 years)

Elderly (≥ 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

# Description of the population covered by the data source in the catchment area whose data are not collected (e.g., people who are registered only for private care)

Data source is a collection of data from different European cohorts of subjects at risk or in preclinical or early stages of Alzheimer's Disease. In all cases, based on consent to participation in the research study, but with different inclusion criteria and sources of recruitment (e.g. memory clinic, advertisement, etc).

# **Population**

# **Population size**

3368

# Population by age group

Age group	Population size
Adults (46 to < 65 years)	1323
Elderly (≥ 65 years)	2045
Adults (65 to < 75 years)	1431
Adults (75 to < 85 years)	519

Age group	Population size
Adults (85 years and over)	95

# Median observation time

Median time (years) between first and last available records for unique individuals captured in the data source

0.50

# Data flows and management

# Access and validation

#### **Governance details**

Documents or webpages that describe the overall governance of the data source and processes and procedures for data capture and management, data quality check and validation results (governing data access or utilisation for research purposes).

AMYPAD PNHS - Data Access Request

# **Biospecimen access**

Are biospecimens available in the data source (e.g., tissue samples)?

No

# Access to subject details

Can individual patients/practitioners/practices included in the data source be contacted?

No

# Event triggering registration

# Event triggering registration of a person in the data source

Other

# Event triggering registration of a person in the data source, other

Admitted to research cohort

# Event triggering de-registration of a person in the data source

Other

# Event triggering de-registration of a person in the data source, other

Withdraw of consent to be included in Parent Cohort

# **Event triggering creation of a record in the data source**

Inclusion in Parent Cohort

# Data source linkage

#### Linkage

Is the data source described created by the linkage of other data sources (prelinked data source) and/or can the data source be linked to other data source on an ad-hoc basis?

Yes

#### Linkage description, pre-linked

The current version of the dataset integrates information from 10 Parent Cohorts: ALFA+, AMYPAD DPMS, DELCODE, EMIF-AD (60++ and 90+), EPAD LCS, FACEHBI, F-PACK, Microbiota, and UCL-2010-412

Each participant enrolled in the AMYPAD PNHS study received a unique identifier that was matched by the parent cohort to their original unique identifier.

Linkage Strategy - Deterministic

Linkage is based on unique subject identifier (person\_id) and visit identifier

(visit\_id)

# Linked data sources

#### **Pre linked**

Is the data source described created by the linkage of other data sources?

No

# Data source, other

ALFA+

# **Linkage strategy**

Deterministic

#### **Pre linked**

Is the data source described created by the linkage of other data sources?

No

# Data source, other

**AMYPAD DPMS** 

# **Linkage strategy**

Deterministic

#### **Pre linked**

No
Data source, other
DELCODE
Linkage strategy
Deterministic
Pre linked
Is the data source described created by the linkage of other data sources?
No
Data source, other
EMIF-AD 60++
Links and standards
Linkage strategy
Deterministic
Pre linked
Is the data source described created by the linkage of other data sources?
No
Data source, other
EMIF-AD 90+
Linkage strategy
Deterministic

Is the data source described created by the linkage of other data sources?

Is the data source described created by the linkage of other data sources?	
No	
Data source, other	
EPAD LCS	
Linkage strategy	
Deterministic	
Pre linked	
Is the data source described created by the linkage of other data sources?	
No	
Data source, other	
FACEHBI	
Linkage strategy	
Deterministic	
Pre linked	
Is the data source described created by the linkage of other data sources?	

# Linkage strategy

Deterministic

Pre linked	Pre	lin	ked
------------	-----	-----	-----

Is the data source described created by the linkage of other data sources?

No

# Data source, other

Microbiota

# Linkage strategy

Deterministic

#### **Pre linked**

Is the data source described created by the linkage of other data sources?

No

# Data source, other

UCL-2010-412

# Linkage strategy

Deterministic

Data management specifications that apply for the data source

#### **Data source refresh**

Every 6 months

# Informed consent for use of data for research

Other

# Possibility of data validation

Can validity of the data in the data source be verified (e.g., access to original medical charts)?

No

# **Data source preservation**

Are records preserved in the data source indefinitely?

Yes

# **Approval for publication**

Is an approval needed for publishing the results of a study using the data source?

Yes

# Informed consent, other

Not applicable when project aims aligns with original project description

# Data source last refresh

01/06/2023

# Common Data Model (CDM) mapping

#### **CDM** mapping

Has the data source been converted (ETL-ed) to a common data model?

Yes

# **CDM Mappings**

OMOP	
CDM website	
https://www.ohdsi.org/Data-standardization/	
Data source ETL CDM version	
5.4	
Data source ETL frequency	
6,00 months	
Data source ETL status	
Completed	
Data source ETL specifications (link)	
https://github.com/AMYPAD/ETL-PNHS	

**CDM** name